A National Academy of Sciences report on ways to cut drug prices -- to be featured at a Senate health committee hearing next Tuesday (Dec. 12) -- includes proposals that run counter to the interests of brand drug makers, pharmacy benefit managers and health plans. The report calls for consolidating government purchasing power, strengthening formulary design, sharing rebates with beneficiaries, publicizing profits of supply chain middlemen and cracking down on hospital drug discounts among its many recommendations. To achieve those...